Tags: Drug.
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug under investigation by GlaxoSmithKline for treatment of type 2 diabetes.It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide has a half-life of four to seven days which is considerably longer than the other two GLP-1 analogs approved for market use exenatide (Byetta) and liraglutide (Victoza).